"To identify more precisely which drugs are likely to be more effective -- or less effective and more toxic -- will have a substantial impact on optimizing health care delivery and rationally curbing costs. In no discipline is this more keenly needed than in cancer care where drugs can be extremely costly and toxic," said Patrick J. Loehrer Sr., M.D., director of the IU Simon Cancer Center.
IU scientists have been working on related research for at least a decade, but creating an institute "allows you to really jump start research and raise the level participation of an institution in both the laboratory and in the clinic, in a broad range of research interests," Dr. Flockhart said.
For example, Janet Carpenter, Ph.D., R.N., professor in the School of Nursing and a member of the institute, sees personalized medicine playing a key role in improving the treatment of menopause.
"About 6,000 American women enter menopause every day yet personalized medicine has not been well-integrated into their health care," she said. "The institute will play a very important role in ensuring that women receive the most appropriate and effective menopausal symptom management therapies."
Mathew Palakal, Ph.D., associate dean for graduate studies and research at the School of Informatics noted that "research in personalized medicine spans a broad spectrum from systems biology to nanomedicine to gene therapy. Our research in such areas as systems biology, biological network analysis and proteomics, along with our graduate programs in health informatics and bioinformatics, will
|Contact: Eric Schoch|
Indiana University School of Medicine